Competitor Analysis: Immunotherapy of Alzheimer's Disease
Competitor Analysis: Immunotherapy of Alzheimer’s Disease
The Competitive Intelligence Report Immunotherapy of Alzheimer’s Disease as of May 2012 provides a competitor analysis in the development pipeline of novel antibodies and vaccines for passive and active immunotherapy of Alzheimer’s disease including those targeting amyloid-beta (beta-amyloid) and tau. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of novel antibodies and vaccines for passive and active imunotherapy of Alzheimer’s disease. In addition, the report lists company-specific R&D pipelines of immunotherapeutics for Alzheimer’s disease. Competitor projects are listed in a tabular format providing Information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitive Intelligence Report Immunotherapy of Alzheimer’s Disease as of May 2012 provides a competitor analysis in the development pipeline of novel antibodies and vaccines for passive and active immunotherapy of Alzheimer’s disease including those targeting amyloid-beta (beta-amyloid) and tau. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of novel antibodies and vaccines for passive and active imunotherapy of Alzheimer’s disease. In addition, the report lists company-specific R&D pipelines of immunotherapeutics for Alzheimer’s disease. Competitor projects are listed in a tabular format providing Information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product category/Therapeutic Area,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
INDEX
1 PASSIVE IMMUNOTHERAPY
Antibodies against amyloid
Antibodies against tau
Antibodies against other targets
Intravenous Immunoglobulin (IVIG)
2 ACTIVE IMMUNOTHERAPY
Vaccines against amyloid
Vaccines against tau
3 CORPORATE AD IMMUNOTHERAPY R&D PIPELINES
4 ABOUT LA MERIE
1 PASSIVE IMMUNOTHERAPY
Antibodies against amyloid
Antibodies against tau
Antibodies against other targets
Intravenous Immunoglobulin (IVIG)
2 ACTIVE IMMUNOTHERAPY
Vaccines against amyloid
Vaccines against tau
3 CORPORATE AD IMMUNOTHERAPY R&D PIPELINES
4 ABOUT LA MERIE
